About PathAI
PathAI focuses on improving patient outcomes by using an AI-powered pathology platform. This platform enhances the accuracy of medical diagnoses and the effectiveness of treatments for diseases like cancer through advanced machine learning techniques. PathAI provides diagnostic tools and services to healthcare providers, research institutions, and pharmaceutical companies, generating revenue through partnerships, licensing, and service fees. What sets PathAI apart from its competitors is its commitment to solving complex healthcare problems with a diverse team dedicated to making a significant impact. The company's goal is to ensure better patient outcomes by delivering precise diagnostic solutions.
Boston, MassachusettsHeadquarters
2016Year Founded
$251.6MTotal Funding
DEBTCompany Stage
AI & Machine Learning, HealthcareIndustries
201-500Employees
Benefits
Competitive medical, dental, and vision insurance
Retirement plan options
Paid parental leave
Health & wellness benefits
Flexible work options
Generous paid time off
Risks
Increased competition from companies like Deep Bio may pose competitive disadvantages.
Quest's acquisition of PathAI Diagnostics' assets may shift focus from core AI development.
Expansion into Europe may expose PathAI to new regulatory challenges and compliance risks.
Differentiation
PathAI offers AI-powered pathology solutions enhancing diagnostic accuracy and treatment efficacy.
The company provides end-to-end automation for scalable, cost-effective pathology solutions.
PathAI's AISight Dx platform streamlines digital pathology workflows with advanced collaboration tools.
Upsides
PathAI's CE mark certification enables expansion into the European diagnostic pathology market.
Strategic partnerships with Quest and Clario enhance AI adoption in pathology.
AI-based tools like AIM-MASH improve assessment accuracy in metabolic dysfunction-associated diseases.
Funding
Total raised$251.65 M
Latest valuation$825.00 M
StageDEBT
DEBT
12/31/2021$100
$15
$75.00 MEARLY VC
2/28/2018$1
$650.00 M$11
$60.00 MSEED
11/30/2016$4
$21.00 M